Pancreatoblastoma is the most common pancreatic malignant tumor of childhood, typically occurring between ages 1-8 years. It has been rarely reported in adults. It presents as a large, well-defined, mixed solid-cystic mass. Calcification is common (30-70%). Elevated serum alpha-fetoprotein (AFP) is a diagnostic clue and is used for monitoring treatment response. Unlike ductal adenocarcinoma, prognosis is better — 5-year survival reaches 50-60% with complete resection.
Age Range
1-8
Peak Age
5
Gender
Male predominant
Prevalence
Rare
Pancreatoblastoma originates from embryonal differentiation of pancreatic acinar cells. Histologically, it contains acinar, ductal, endocrine, and 'squamoid corpuscle' components — this multidirectional differentiation reflects embryonal pancreatic tissue. The tumor's large size and well-defined capsule manifest as prominent mass effect and sharp margins on imaging. Calcifications arise from dystrophic calcification of squamoid corpuscles. The mixed solid-cystic architecture reflects necrosis and hemorrhagic degeneration. AFP elevation indicates the tumor's shared embryonal cell origin with hepatoblastoma. Association with Beckwith-Wiedemann syndrome and familial adenomatous polyposis (FAP) has been reported.
The combination of a large, well-defined, calcified mixed solid-cystic pancreatic mass with elevated serum AFP in a child aged 1-8 years is the most specific finding combination for pancreatoblastoma. No other childhood pancreatic tumor shows this combination as typically.
On non-contrast CT, a large (usually >5 cm), well-defined mass with heterogeneous attenuation is identified. Coarse or punctate calcifications are seen in 30-70% of patients. Low-attenuation areas represent necrosis and cystic degeneration.
Report Sentence
A large, well-defined, heterogeneous mass with internal coarse calcifications is identified in the pancreas; pancreatoblastoma should be considered in the pediatric context.
In the arterial phase, heterogeneous enhancement is observed in solid components. Cystic and necrotic areas show no enhancement. Capsular enhancement is possible. Vascular invasion may be seen in adult types but is rare in childhood forms.
Report Sentence
In the arterial phase, heterogeneous enhancement is observed in the solid components of the mass while cystic/necrotic areas show no enhancement.
On T1-weighted MRI, the tumor is typically heterogeneously hypointense. Hemorrhagic areas show focal T1 hyperintensity. Calcifications appear as low signal foci. The capsule may be seen as a thin hypointense ring on T1.
Report Sentence
Heterogeneously hypointense signal is observed in the mass on T1-weighted sequences with focal hyperintense areas consistent with internal hemorrhage.
On T2-weighted MRI, the tumor shows heterogeneously hyperintense signal. Cystic/necrotic components appear markedly hyperintense, solid components show intermediate signal. The capsule is clearly seen as a hypointense ring on T2. Septae and internal structures are better evaluated on T2.
Report Sentence
Heterogeneously hyperintense signal is observed in the mass on T2-weighted sequences with markedly hyperintense cystic/necrotic components and a hypointense capsular structure.
On ultrasonography, pancreatoblastoma appears as a large, heterogeneous, well-defined mass. Solid components are hypoechoic-isoechoic, cystic areas are anechoic. Calcifications are identified as hyperechoic foci with posterior acoustic shadowing.
Report Sentence
A large, heterogeneous, well-defined mass with internal calcifications and cystic components is identified in the pancreas.
On DWI, diffusion restriction is observed in solid components — reflecting high cellularity. Cystic and necrotic areas show no diffusion restriction. This distribution is useful for surgical planning and treatment response assessment.
Report Sentence
Diffusion restriction limited to solid components is observed in the mass on DWI, consistent with active tumor tissue.
Criteria
Age 1-8 years, large mass (>5 cm), calcification, elevated AFP, well-defined encapsulated
Distinct Features
Most common type. Good prognosis with complete resection (5-year survival 50-60%). Good chemotherapy response. Association with Beckwith-Wiedemann syndrome reported.
Criteria
>18 years, rare, more aggressive course, vascular invasion more common
Distinct Features
Very rare (<5%). More aggressive than childhood form. AFP elevation less frequent. Vascular invasion and metastasis earlier. Worse prognosis.
Criteria
Diagnosis at birth or first month, usually large abdominal mass, can be detected on prenatal US
Distinct Features
Rarest form. May be incidentally detected on prenatal US. AFP interpretation requires caution as it is physiologically elevated at birth. Prognosis similar to childhood form if complete resection possible.
Distinguishing Feature
SPN typically occurs in young women (20-30 years) — pancreatoblastoma in childhood (1-8 years). Calcification in SPN is peripheral and punctate while in pancreatoblastoma it is coarse and central. AFP is elevated in pancreatoblastoma, normal in SPN.
Distinguishing Feature
pNET is typically seen in adults and shows homogeneous hypervascular arterial phase enhancement. Pancreatoblastoma occurs in childhood, has heterogeneous enhancement, and calcification is more common. Chromogranin A is elevated in pNET, AFP is elevated in pancreatoblastoma.
Distinguishing Feature
Acinar cell carcinoma occurs in adults and may be accompanied by lipase hypersecretion syndrome. Both tumors are large and well-defined, but pancreatoblastoma is distinguished by childhood presentation, AFP elevation, and more frequent calcification. Histologically, squamoid corpuscles are specific to pancreatoblastoma.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralSurgical resection is the fundamental treatment approach for pancreatoblastoma. Complete resection (R0) achieves 5-year survival of 50-60%. In unresectable or metastatic cases, neoadjuvant chemotherapy (cisplatin-based regimens) can be applied — tumor downsizing may enable resectability. Serum AFP is used for treatment response and recurrence monitoring. Liver and lung are the most common metastatic sites. A multidisciplinary team approach involving pediatric oncology, pediatric surgery, and radiology is required.
Pancreatoblastoma is treated with surgical resection and has a better prognosis than PDAC. Survival rates are high when complete resection is achieved. Chemotherapy may be used as neoadjuvant or adjuvant therapy. AFP can be used as a follow-up marker.